The Mass Cytometry Summit 2021 – Igniting Insight into Human Health

Michael Fehlings, PhD., ImmunoScape’s VP of Operations and Development, will be presenting on,”SARS-CoV-2 specific CD8+ T cell responses in convalescent COVID-19 individuals” on May 25 at 11:00-11:30 am PT.
The CyTOF® Edge will be a half day virtual event taking place on 25th May 2021.
The focus will be on clinical and translational investigators using CyTOF technology to gain cell biology insights and develop new ways to diagnose and treat human disease in the areas of immunooncology and infectious disease research.

Click to get more information

The Bio Report Podcast: Characterizing the Immunome at Scale

ImmunoScape’s Senior Director of Business Development/Lead of the Vaccine Task Force, Dr. Brian Abel did a Bio Report podcast with Daniel Levine on Characterizing the Immunome at Scale discussing a collaborative study with National Institutes of Health’s National Institute of Allergy and Infectious Diseases and Johns Hopkins University about the ability of people infected with COVID-19 to produce an immune response to new variants of the virus, the company’s technology, and how it is being used to develop the next generation of immunotherapies.
Click here to hear the podcast

BIOCOM 2021

Geoff Nosrati, Ph.D., ImmunoScape’s Chief Business Officer, will be presenting on, “Advancing the development of next-generation therapeutics with the Deep Immunomics platform.” at Biocom’s upcoming Global Life Science Partnering Conference.

Session date: February 25th, 2021

Session time: 10:00-10:14am PST

Presentation

Click to get more information

World Vaccine & Immunotherapy 2020

World Vaccine & Immunotherapy 2020

Please join our oral presentation on, “Broad and Prevalent SARS-CoV-2 CD8+ T Cell Response in Recovered COVID-19 Individuals Demonstrates Kinetics of Early Differentiation” and meet our team.

Session Date: Tuesday, December 1, 2020

Session Time: 4:20 PM PST

Come visit ImmunoScape’s virtual booth at the WVIC 2020, December 1-3, 2020 and chat with us.


CD8+ T cell responses in convalescent COVID-19 individuals target epitopes from the entire SARS-CoV-2 proteome and show kinetics of early differentiation

In this study, using our multiplexed peptide-MHC tetramer approach to screen 408 SARS-CoV-2 candidate epitopes for CD8+ T cell recognition, we identified 52 unique epitope hits (18 unreported), spanning different viral proteins. Insights gained from these SARS-CoV-2 reactivities and their associated T cell profiles capable of differentiating into long-term mediators of protection may guide the rational design of COVID-19 vaccine candidates to curb this pandemic.

Click to get more information on the conference. 

IDWeek 2020

IDWeek 2020™

October 21-25, 2020

 

Please join our oral presentation on, “Broad and Prevalent SARS-CoV-2 CD8+ T Cell Response in Recovered COVID-19 Individuals Demonstrates Kinetics of Early Differentiation” and meet our team!

Session Date: Saturday October 24, 2020

Session Time: 1:15 PM – 3:00 PM

Come visit ImmunoScape’s virtual booth at the IDWeek 2020™ and chat with us!

 

CD8+ T cell responses in convalescent COVID-19 individuals target epitopes from the entire SARS-CoV-2 proteome and show kinetics of early differentiation

In this study, using our multiplexed peptide-MHC tetramer approach to screen 408 SARS-CoV-2 candidate epitopes for CD8+ T cell recognition, we identified 52 unique epitope hits (18 unreported), spanning different viral proteins. Insights gained from these SARS-CoV-2 reactivities and their associated T cell profiles capable of differentiating into long-term mediators of protection may guide the rational design of COVID-19 vaccine candidates to curb this pandemic.

Click to get more information on this conference

The Digital International Liver Conference™ 2020

August 27-29, 2020

Virtual event

ImmunoScape and Gilead Sciences recently presented findings at the Digital International Liver Congress 2020 that demonstrated the feasibility of simultaneously identifying and deeply characterizing rare HBV-specific T cells in heterogeneous HBV patient cohorts to facilitate the development of more effective therapeutic strategies for hepatitis B virus (HBV) infection.

Poster

Click here for more information on this conference.

BIO Digital

June 8-12, 2020
New Virtual Event

When collaboration is more vital than ever, you can still rely on BIO to bring the industry together. For 2020, the BIO International Convention will transition to a new, virtual event format, BIO Digital. This virtual gathering of the global biotech industry provides access to key partners via BIO One-on-One Partnering, educational resources to help drive your business, and the insights you need to continue critical research and development. We may not be able to gather in person, but nothing stops innovation.

Click here to learn more about this conference.

ASCO 2020 Virtual

ASCO20 Virtual Scientific Program

May 29-31, 2020
New Virtual Event

ASCO will deliver the latest cancer science to the global community in this year’s ASCO20 Virtual Scientific Program.  The program will feature over 250 oral abstract presentations and 2,500 poster presentations in 24 disease-based and specialty tracks.Content will be delivered in two formats – on-demand and scheduled broadcasts. The on-demand content will be available starting on Friday, May 29, and will include posters and scientific sessions not covered in the scheduled broadcast. Sessions will be broadcast on May 30-31 from 9:30am – 5:00pm ET.

Click here to learn more about this conference.

AACR Annual Meeting 2020 | Turning Science into Lifesaving Care

April 24-29, 2020
San Diego Convention Center
San Diego, CA

The AACR Annual Meeting program covers the latest discoveries across the spectrum of cancer research—from population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy—and highlights the work of the best minds in research and medicine from institutions all over the world.

Click here to learn more about this conference.

Advances in Cancer Immunotherapy | Keystone Symposia

March 22-26, 2020
Fairmont Chateau Whistler
Whistler, BC Canada

Visit our poster number 1001 on Monday, March 23, 2020 at Poster Session 1

Immuno-phenotyping of tumor-specific CD8 T cells using high-dimensional mass cytometry.

Cancer immunotherapy is providing an unprecedented level of long-term antitumor activity in some patients, but unfortunately the majority of patients still do not experience sustained clinical benefit. Many questions remain unanswered. The conference program will include sessions which cover topics such as new analysis techniques, methodologies, and how to integrate high throughput data to provide a more comprehensive understanding of cancer and the immune system.

Click here to learn more about this conference.